medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 4

<< Back Next >>

Medicina & Laboratorio 2022; 26 (4)

Reactive lymphadenopathy due to Pfizer-BioNTech COVID-19 vaccine: a case report

Correa-Flórez S, Caviedes MA, Salamanca-Flórez Á, Mondragón-Cardona Á

Language: Spanish
References: 8
Page: 375-381
PDF size: 320.55 Kb.


ABSTRACT

One of the side effects found in patients with a history of vaccination for COVID-19, especially with the Pfizer-BioNTech vaccine, is the appearance of multiple hyperplastic adenopathies, mainly axillary, supraclavicular and infraclavicular lymph nodes ipsilateral to the vaccination site. We present the case of a 33-year- old female patient, with the appearance of a painful left supraclavicular mass, who was vaccinated a week earlier with the first dose of the Pfizer-BioNTech vaccine in the left deltoid region. The cytological findings were suggestive of a lymphoproliferative disease, and the histopathological study revealed reactive lymphadenopathy with proliferation of activated B immunoblasts, secondary to vaccination against COVID-19. We contribute to the literature with the characterization of the histopathological findings of COVID-19 post-vaccination lymphadenopathy. It is important for treating physicians and radiologists to be familiar with this differential diagnosis, in order to provide appropriate recommendations based on short-term follow-up, instead of performing unnecessary immediate biopsies or interventions in patient management.


REFERENCES

  1. García-Molina F, Cegarra-Navarro MF, Andrade-Gonzales RJ, Martínez-Díaz F. Cytologicand histologic features of COVID-19 postvaccinationlymphadenopathy. Cytojournal 2021;18:34. https://doi.org/10.25259/Cytojournal_21_2021.

  2. Mehta N, Sales RM, Babagbemi K, Levy AD,McGrath AL, Drotman M, et al. Unilateral axillaryadenopathy in the setting of COVID-19vaccine. Clin Imaging 2021;75:12-15. https://doi.org/10.1016/j.clinimag.2021.01.016.

  3. Hiller N, Goldberg SN, Cohen-CymberknohM, Vainstein V, Simanovsky N. Lymphadenopathyassociated with the COVID-19 vaccine.Cureus 2021;13:e13524. https://doi.org/10.7759/cureus.13524.

  4. Centers for Disease Control and Prevention(CDC). Vaccines & Immunizations. Pfizer-BioNTech COVID-19 vaccine reactions &adverse events. Atlanta, Georgia: CDC; 2022.Acceso 22 de mayo de 2022. Disponible enhttps://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html.

  5. Weiss LM, O'Malley D. Benign lymphadenopathies.Mod Pathol 2013;26:S88-96. https://doi.org/10.1038/modpathol.2012.176.

  6. Cohen J, Powderly WG, Opal SM. InfectiousDiseases. Amsterdam, Netherlands: ElsevierHealth Sciences; 2017. p. 145. ISBN:9780702079351.

  7. Studdiford J, Lamb K, Horvath K, AltshulerM, Stonehouse A. Development of unilateralcervical and supraclavicular lymphadenopathyafter human papilloma virus vaccination.Pharmacotherapy 2008;28:1194-1197.https://doi.org/10.1592/phco.28.9.1194.

  8. Bshesh K, Khan W, Vattoth AL, Janjua E,Nauman A, Almasri M, et al. Lymphadenopathypost-COVID-19 vaccination withincreased FDG uptake may be falsely attributedto oncological disorders: A systematicreview. J Med Virol 2022;94:1833-1845.https://doi.org/10.1002/jmv.27599.




2020     |     www.medigraphic.com